{"commentary":{"count":6,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":3,"x_thread":2,"youtube":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"NCT05870319","nct_id":"NCT05870319","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05870319. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":null,"label":"SKB264 by IV infusion on Days 1 and 15 of each 4-week cycle;","type":"EXPERIMENTAL"},{"description":null,"label":"pemetrexed+ carboplatin or on Day 1 of each 3-week cycle, with 4 cycles chemo","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-09-30","type":"ESTIMATED"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":376,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"SKB264","type":"DRUG"},{"name":"Pemetrexed","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"},{"name":"Cisplatin","type":"DRUG"}],"last_update":"2026-05-08","lead_sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","official_title":"A Randomized, Open-Label, Multicenter Phase 3 Study to Evaluate SKB264 Monotherapy Versus Pemetrexed in Combination With Platinum in Patients With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutation Who Have Failed to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Therapy","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-07-11","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free survival (PFS)","timeFrame":"From baseline until disease progression, death, or other protocol defined reason,up to approximately 36 months"}],"references":[{"citation":"Fang W, Wu L, Meng X, Yao Y, Zuo W, Yao W, Xie Y, Zhang Y, Cui J, Zhang Y, Li X, Zhuang W, Fang J, Wang Q, Jiang W, Li K, Bai Y, Luo Y, Ma F, Yu Y, Zheng W, Liu Z, Yang B, Ma R, Fang Y, Yang R, Jiang L, Hu J, Yang J, Diao Y, Jin X, Ge J, Yang Y, Zhang L. Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2026 Jan 1;394(1):13-26. doi: 10.1056/NEJMoa2512071. Epub 2025 Oct 19.","pmid":"41124220","type":"DERIVED"}],"start_date":{"date":"2023-06-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients","url":"https://clinicaltrials.gov/study/NCT05870319"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05870319"}